Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Walker

Pain Medicine Nashville, TN Medical Doctor

NPI 1699062364 CMS profile 1066045

3601 The Vanderbilt Clinic, Nashville, TN 37232

Open in the dashboard

General payments

$25,076

81 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Walker of Nashville, TN is reported in the CMS Open Payments database as having received $25,076 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $195 2
2024 General $391 2
2023 General $246 5
2022 General $272 3
2019 General $23,973 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Walker
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jeremy Walker were reported at $195. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Jeremy Walker Pain Medicine median Middle half National median
2019 $23,973 $506 $144–$1,566 $163
2020 $0 $315 $96–$934 $114
2021 $0 $452 $134–$1,237 $132
2022 $272 $475 $124–$1,407 $149
2023 $246 $480 $136–$1,384 $160
2024 $391 $521 $164–$1,511 $164
2025 $195 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $22,471 51 payments
  2. Boston Scientific Corporation $1,326 11 payments
  3. Medtronic, Inc. $543 6 payments
  4. Saluda Medical Americas, Inc. $298 2 payments
  5. Abbott Laboratories $265 3 payments
  6. Stryker Corporation $66 2 payments
  7. BIOTRONIK NRO, Inc. $28 1 payment
  8. Flowonix Medical Incorporated $25 1 payment
  9. Flexion Therapeutics, Inc. $21 1 payment
  10. Pfizer Inc. $11 1 payment
  11. Other $22 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,153 15 payments
  2. Food and Beverage $3,158 50 payments
  3. Travel and Lodging $2,740 15 payments
  4. Entertainment $25 1 payment
Products named General payments · program years 2019–2025
  1. RESTORE $9,236 10 payments
  2. ADAPTIVESTIM $8,079 12 payments
  3. INTELLIS $4,674 27 payments
  4. SPECTRA WAVEWRITER $1,262 9 payments
  5. INTELLIS ADAPTIVESTIM $495 4 payments
  6. SYNCHROMED $358 1 payment
  7. PROCLAIM $168 1 payment
  8. Evoke $167 1 payment
  9. Evoke SCS $131 1 payment
  10. Proclaim Family of SCS IPGs $97 2 payments
  11. Other $297 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,622

Median for Anesthesiology: 322

Drug cost

$78,692

Median for Anesthesiology: $8,738

Branded share of claims

23%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 118 $35,449
Belbuca Buprenorphine Hcl Brand 12 $7,825
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 42 $3,919
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 12 $3,614
Oxycontin Oxycodone Hcl Brand 14 $3,570
Gabapentin Generic 169 $3,256
Memantine Hcl Generic 129 $3,169
Lidocaine Generic 24 $2,865
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 177 $2,541
Pregabalin Generic 104 $2,384

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$198,658

Of which drugs: $12,113

Medicare patients

449

Average age 73

Services billed

16,322

279 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 36%
Ischemic heart disease 33%
Diabetes 28%
Chronic kidney disease 28%
COPD 19%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 104 6,600 $640
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 111 5,640 $575
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 45 478 $41

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record